home / stock / cdna / cdna news

CDNA News and Press, CareDx Inc.

Stock Information
Company Name: CareDx Inc.
Stock Symbol: CDNA
Market: NASDAQ
Menu
CDNA CDNA Quote CDNA Short CDNA News CDNA Articles CDNA Message Board
Get CDNA Alerts

News, Short Squeeze, Breakout and More Instantly...
CDNA - (CDNA) Investment Analysis

2024-06-20 11:54:00 ET Stock Traders Daily has produced this trading report using a proprietary method.  This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
CDNA - Landmark Independent Publication in Nature Medicine Validates CareDx AlloView AI-Enabled Risk Prediction Model and Demonstrates AlloSure Kidney Detects Subclinical Rejection in Stable Patients

Surveillance Monitoring with Both AlloSure Kidney and the AlloView AI-Enabled Risk Prediction Model Improves the Detection of All Types of Allograft Rejection AlloSure Kidney Detected Subclinical Rejection in Clinically Stable Patients and AlloSure Kidney dd-cfDNA Levels were Elevated Pri...

CDNA - AI Integration and Real-World Utility of CareDx Portfolio Highlighted in New Data at the 2024 American Transplant Congress

AI-Derived AlloView Results Correlate with Presence and Type of Biopsy Proven Kidney Rejection Longitudinal Monitoring with AlloSure Kidney Enables Earlier Identification of Graft Injury and Assessment of Rejection Treatment KOAR Data Show Kidney Biopsies Informed by AlloSure Dete...

CDNA - CareDx Reiterates Position that it Does Not Infringe the '544 Patent, Injunction Motion is Irrelevant

CareDx Reiterates Position that it Does Not Infringe Natera’s ‘544 Patent Injunction Motion has No Impact on CareDx’s Business or Patient and Clinician Access to AlloSure or AlloMap CareDx, Inc. (Nasdaq: CDNA) – The Transplant Company™ focused ...
CDNA - Landmark Study Shows CareDx's HeartCare Outperforms dd-cfDNA Alone in Identifying Rejection and Patients Experienced Excellent Outcomes with Fewer Biopsies

HeartCare Results Effectively Stratified Patients at Highest Risk for Acute Cellular Rejection Cardiologists Performed the Fewest Biopsies After Dual Negative HeartCare Results Compared to Single or Dual Positive Results Two-Year Clinical Outcomes Data Demonstrate Excellent Surviv...

CDNA - Market Perform Recommendation Issued On CDNA By Raymond James

2024-05-13 16:15:04 ET Raymond James analyst issues MARKET PERFORM recommendation for CDNA on May 13, 2024 02:30PM ET. The previous analyst recommendation was Outperform. CDNA was trading at $15.12 at issue of the analyst recommendation. The overall analyst consensus : B...

CDNA - CareDx cut to market perform by Raymond James over valuation

2024-05-13 15:07:16 ET More on CareDx CareDx, Inc. (CDNA) Q1 2024 Earnings Call Transcript CareDx, Inc 2024 Q1 - Results - Earnings Call Presentation CareDx, Inc. (CDNA) Q4 2023 Earnings Call Transcript CareDx rises as much as 38%, highest intraday gain in si...
CDNA - US Companies Moving the Markets, Evening edition
Fri, May 10, 2024 as of 4:00 pm ET

A look at the top 10 most actives in the United States Novavax Inc. (NVAX) rose 98.7% to $8.88 on volume of 168,692,127 shares AEye Inc. (LIDR) rose 115.0% to $2.58 on volume of 156,236,079 shares Ginkgo Bioworks Holdings Inc. Class A (DNA) fell 17.3% to $0.7609 on volume of 123,678,040 s...

CDNA - CareDx rises as much as 38%, highest intraday gain in six years

2024-05-10 13:45:54 ET More on CareDx CareDx, Inc. (CDNA) Q1 2024 Earnings Call Transcript CareDx, Inc 2024 Q1 - Results - Earnings Call Presentation CareDx, Inc. (CDNA) Q4 2023 Earnings Call Transcript CareDx Q1 2024 Earnings Preview CareDx Q4 2023 E...

CDNA - NVAX, GRPN and MVIS among mid-day movers

2024-05-10 12:57:54 ET Gainers: Novavax NVAX +106% . AEye LIDR +67% . ITeos Therapeutics ITOS +48% . Sensus Healthcare SRTS +35% . Inseego Corp INSG +32% . Sweetgreen SG +33% . Organogenesis Holdings ORGO +33% . Caredx CDNA +32...
Next 10